Key Highlights
- Significant reduction in healthcare resource use (HCRU) and surgical revisions demonstrated in patients using PROPEL devices post-ESS.
- Study leverages OM1’s real-world data and collaboration with the AAO-HNSF through the Reg-entSM registry.
- Potential for expanded payer coverage due to positive impact on cost savings and patient care standards.
Source: Business Wire
Notable Quote
- “The results of this study demonstrate a rare win-win-win within healthcare. By reducing postoperative inflammation and follow-up interventions, we have the opportunity to elevate the standard of care for CRS patients, decrease the burden of revision surgeries for physicians, and reduce healthcare utilization costs for the entire industry,” – Amy Van Sach, President at Medtronic ENT
SoHC's Take
This recent collaboration between OM1 and Medtronic highlights an essential step forward in managing chronic rhinosinusitis, particularly through the innovative use of PROPEL devices in endoscopic sinus surgery. By effectively reducing the need for additional interventions and the associated healthcare costs, the study not only supports the clinical efficacy of the PROPEL devices but also points towards a sustainable model for healthcare systems dealing with high volumes of sinus surgery cases. This is a quintessential example of how targeted medical technology can significantly enhance both economic outcomes and patient care quality.
